Mallinckrodt completes acquisition of Cadence Pharmaceuticals

DUBLIN — Mallinckrodt, a specialty pharmaceuticals company, announced the completion of its acquisition of Cadence Pharmaceuticals for approximately $1.4 billion.



The acquisition adds Ofirmev (acetaminophen) injection to Mallinckrodt’s roster of brands and its specialty pharmaceuticals portfolio of controlled substance specialty generics.The drug is used to manage mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever, the company said. Ofirmev also will expand Mallinckrodt presence in the U.S. hospital channel.



“We are excited by the opportunities provided by Ofirmev, which will significantly expand Mallinckrodt’s ability to serve U.S. hospitals,” said Mark Trudeau, resident and CEO of Mallinckrodt. “As anticipated, the transaction was straightforward, closed quickly, and we are planning for a rapid and successful integration, which we expect to be completed by the beginning of September. We believe this accelerated integration will provide greater clarity and direction for the employees joining us, and ensure that the merger of Ofirmev and the transition of the hospital team into Mallinckrodt is smooth and best serves our customers.”